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1. Introduction
Enterococci are the natural members of the gastrointestinal 
tract, mouth, urethra, and vaginal flora and may result in 
serious nosocomial infections despite their low virulence 
characteristics. Enterococci are often isolated particularly 
from patients in intensive care units with suppressed 
immune systems, hematological malignancies, catheter 
and prosthesis existence, prolonged hospitalization 
duration, and usage of broad-spectrum antibiotics (1).
The first vancomycin-resistant Enterococcus strain 
in the world was reported by Uttley et al. (2) in the 
UK in 1988. In Turkey, the first vancomycin-resistant 
Enterococcus strain was reported in a pediatric patient by 
Vural et al. (3) from Akdeniz University in 1998. 
Resistance to vancomycin develops with the vanA and 
vanB genes coded by plasmids and vanC, vanD, and vanG 
coded by chromosomes. The most common multidrug 
resistance (MDR)1 genes among them are vanA and vanB. 
It is important for the pathogenesis of illnesses to know 
if enterococci have certain virulence genes other than 
resistance to antibiotics.  
Attachment to epithelial tissue, formation of biofilm, the 
spread of bacteria over connective tissue, the breakdown 
of collagen, and hemolysis occur through proteins coded 
from esp, hyl, gelE, asa1, and cyl gene areas (4,5).
Enterococci, ranking first among causes of nosocomial 
infections, have epidemiologically become more important 
with the presence of both resistance and virulence 
factors. Studies are limited that investigate the presence 
of enterococci with these two characteristics together in 
nosocomial infections. 
Our objective was to investigate both resistance and 
virulence gene areas in patient isolates with vancomycin-
resistant enterococci and vancomycin-sensitive enterococci 
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(VRE and VSE, respectively). We think that the obtained 
data will be epidemiologically useful in understanding the 
pathogenesis of enterococci. 
2. Materials and methods
A total of 116 Enterococcus strains isolated from patients 
in various clinics of the Ankara and Adana hospitals of the 
Başkent University Faculty of Medicine were included in 
the study. If more than one sample was available from the 
same patient, only one sample was included in the study.  
2.1. Identification of bacteria
Strains were kept in glycerol bouillon at –86 °C and then 
transferred for culture to 5% sheep blood agar media 
(Becton Dickinson, USA) and incubated at 37 °C for 24 
h. In gram-positive coccus morphology, catalase-negative 
strains were applied for the PYR test with the BBL DrySlide 
PYR kit (Becton Dickinson). Isolates were also cultured 
in esculin medium and 6.5% NaCl medium. Strains 
with positive PYR test results, producing black colonies 
in the esculin medium and growing in 6.5% NaCl, were 
identified to be Enterococcus spp., and the species were 
further identified by Rapid ID 32 Strep kits (BioMérieux, 
France). Identifications of species were verified by the 
MALDI-TOF system (BioMérieux).
2.2. Determination of sensitivity of bacteria to antibiotics
2.2.1. Determination of sensitivity to vancomycin 
2.2.1.1. Kirby–Bauer disk diffusion method 
Sensitivity to vancomycin was assessed using 30-µg 
vancomycin disks in Mueller Hinton agar (Becton 
Dickinson) medium in accordance with recommendations 
of the Clinical and Laboratory Standards Institute (6). 
2.2.1.2. Determination of minimal inhibitor 
concentration (MIC) with broth microdilution method
Vancomycin resistance/sensitivity was verified by the 
broth microdilution method. For determination of MICs, 
the broth microdilution method, Mueller Hinton II broth 
medium (Becton Dickinson), and standard powder of 
vancomycin (Sigma, Germany) were used (6). All tests 
were repeated twice. E. faecalis ATCC 29212 and S. aureus 
ATCC 29213 were used as quality control strains for each 
study. For all VRE strains, vancomycin MIC values were 
≥128 µg/mL.
2.2.2. Determination of sensitivity to teicoplanin 
The MIC value of teicoplanin was determined by gradient 
diffusion method. E-test strips (BioMérieux) were used for 
MIC determination. E. faecalis ATCC 29212 was used as a 
quality control strain. For all VRE, teicoplanin MIC values 
were ≥256 µg/mL. 
2.3. Investigation of multidrug resistance and virulence 
genes with polymerase chain reaction (PCR)
DNAs of strains were extracted via gram-positive bacteria 
DNA extraction kit (Genoks, Turkey) and kept at –20 °C 
until DNAs were amplified. Primers described by Dutka-
Malen et al. (7) were used to investigate MDR genes (Table 
1). In investigation of MDR genes, E. faecalis ATCC 51559 
was used as a vanA-positive control strain, E. faecalis 
ATCC 51299 was used as a vanB-positive control strain, 
and E. faecalis ATCC 29212 was used as a negative control 
strain. Primers described by Vankerckhoven et al. (8) were 
used for investigation of virulence genes (Table 2). In 
investigation of virulence genes, E. faecalis MMH594 (for 
esp, cyl, asa1, and gelE) and E. faecium C68 (for hyl) were 
used as positive control strains.
vanA and vanB, esp and cyl, and asa1 and gelE were 
investigated as pairs by multiplex PCR. In the thermal 
cycle (Biometra, Germany), the following phases were 
carried out: at 94 °C for 2 min; then at 94 °C for 45 s, 58 °C 
for 45 s, and 72 °C for 45 s for 35 cycles; and a final cycle 
at 72 °C for 10 min.  
Next, 10 µL of each amplification product was mixed 
with the loading dye and loaded in the tank. A 50-bp DNA 
ladder (O’RangeRuler, Fermentas, Lithuania) was used as 
a molecular standard marker. Electrophoresis was carried 
out at 120 V for 30 min. Bands were imaged with a UV 
transilluminator (TFX 20M, Vilber Lourmat, France).
2.4. Statistical analysis
Data were analyzed by Pearson chi-square test, likelihood 
ratio test, Fisher exact test, and z test depending on the 
frequency of tables and the number of cells in tables. P < 
0.05 was considered to be statistically significant. SPSS 17.0 
was used for data analyses (SPSS Inc., Chicago IL, USA). 
Table 1. Multidrug resistance gene primer sequences (7). 
Gene Primer name  Oligonucleotide sequence (5’ to 3’) Product size (bp)
vanA
A1 5’ GGGAAAACGACAATTGC 3’
732
A2 5’ GTACAATGCGGCCGTTA 3’
vanB
B1 5’ATGGGAAGCCGATAGTC3’
635
B2 5’GATTTCGTTCCTCGACC3’
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3. Results
3.1. Bacterial identification and sensitivity results
Of 116 isolates, 93 (80.2%) were identified to be VRE and 
23 (19.8%) were identified to be VSE. Of the VRE (n = 
93), 95.7% (n = 89) were identified as E. faecium and 4.3% 
(n = 4) were identified as E. faecalis. The most common 
species isolated in this study was E. faecium. Distribution 
of species by clinics for VRE and distribution of species 
by clinical samples for VRE and VSE are presented in 
Tables 3 and 4, respectively. Among VSE (n = 23), the most 
commonly isolated species was E. faecalis at 82.6% (n = 
19), followed by E. faecium at 17.4% (n = 4). 
Table 2. Virulence genes and factors (8).
Gene Virulence factor Primer name Oligonucleotide sequence (5’ to 3’) Product size (bp)
esp Enterococcal surface protein
ESP 14F AGATTTCATCTTTGATTCTTGG 
510
ESP 12R AATTGATTCTTTAGCATCTGG
cyl Cytolysin
CYLI ACTCGGGGATTGATAGGC
688
CYLIIb GCTGCTAAAGCTGCGCTT
asa1 Aggregation substance
ASA11 GCACGC TATTACGAACTATGA
375
ASA12 TAAGAAAGAACATCACCACGA
gelE Gelatinase
GEL11 TATGACAATGCTTTTTGGGAT
213
GEL12 AGATGCACCCGAAATAATATA
hyl Hyaluronidase
HYL n1 ACAGAAGAGCTGCAGGAAATG 
276
HYL n2  GACTGACGTCCAAGTTTCCAA 
Table 3. Distribution of species by clinics for VRE and VSE.
                                           Bacteria
Clinics
VRE VSE
E. faecium E. faecalis Total
P
E. faecium E. faecalis Total
P
n (%) n (%) n (%) n (%) n (%) n (%)
Surgery clinics*
Positive 20 (95.2) 1 (4.8) 21 (100)
0.201
0 2 (100) 2 (100)
0.999
Negative 69 (95.8) 3 (4.2) 72 (100) 4 (19) 17 (81) 21 (100)
Surgery 
polyclinics**
Positive - - -
-
2 (20) 8 (80) 10 (100)
0.999
Negative - - - 2 (15.4) 11 (84.6) 13 (100)
Internal 
polyclinics#
Positive - - -
-
0 5 (100) 5 (100)
0.539
Negative - - - 4 (22.3) 14 (77.7) 18 (100)
Intensive care units
Positive 18 (90) 2 (10) 20 (100)
0.999
0 3 (100) 3 (100)
0.999
Negative 71 (97.3) 2 (2.7) 73 (100) 4 (20) 16 (80) 20 (100)
Other clinics ##
Positive 16 (100) 0 16 (100)
0.999
- - -
-
Negative 73 (94.8) 4 (5.2) 77 (100) - - -
Pediatrics
Positive 13 (100) 0 13 (100)
0.999
1 (50) 1 (50) 2 (100)
0.324
Negative 76 (95) 4 (5) 80 (100) 1 (100) 0 1 (100)
Nephrology
Positive 10 (90.9) 1 (9.1) 11 (100)
0.401
- - -
-
Negative 79 (96.3) 3 (3.7) 82 (100) - - -
Burn units
Positive 7 (100) 0 7 (100)
0.999
- - -
-
Negative 82 (95.3) 4 (4.7) 86 (100) - - -
Hematology
Positive 5 (100) 0 5 (100)
0.999
1 (100) 0 1 (100)
0.174
Negative 84 (95.5) 4 (4.5) 88 (100) 3 (13.7) 19 (86.3) 22 (100)
*General surgery, orthopedics. 
**Urology, general surgery, orthopedics, obstetrics. 
#Pediatrics, rheumatology, dermatology, endocrinology, infectious diseases.
##Neurology, internal medicine, cardiology, geriatrics, physical therapy and rehabilitation, gastroenterology, and chest disease services.
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3.2. Results of molecular analyses 
vanA and vanB were initially investigated in all strains by 
PCR. vanA was detected in all 93 VRE strains (Figure 1). 
PCR images of virulence genes are shown in Figures 2–6. 
The most common virulence factor was esp with a rate 
of 78.4% (n = 91) among all enterococci (n = 116). esp 
was positive in 75 strains (80.6%) out of 93 VRE strains. 
It was followed by hyl (15.1%, n = 14) and gelE (3.2%, n = 
3) in VRE strains (n = 93), respectively. Multiple virulence 
factors were found in VRE (n = 93) strains: esp+hyl 
(12.4%) and esp+gelE (2.2%). Three virulence factors 
were not found together in any VRE strains. Asa1 and cyl 
Table 4. Distribution of species by clinical samples for VRE and VSE.
                                           Bacteria
Clinics
VRE VSE
E. faecium E. faecalis Total
P
E. faecium E. faecalis Total
P
n (%) n (%) n (%) n (%) n (%) n (%)
Urine
Positive 32 (91.4) 3 (8.6) 35 (100)
0.147
2 (18.2) 9 (81.8) 11 (100)
0.999Negative 57 (98.3) 1 (1.7) 58 (100) 2 (16.7) 10 (83.3) 12 (100)
Wounds
Positive 20 (100) 0 20 (100)
0.573
1 (12.5) 7 (87.5) 8 (100)
0.999Negative 69 (94.5) 4 (4.5) 73 (100) 3 (20) 12 (80) 15 (100)
Blood
Positive 18 (100) 0 18 (100)
0.999
1 (50) 1 (50) 2 (100)
0.324Negative 71 (94.6) 4 (5.4) 75 (100) 3 (14.3) 18 (85.7) 21 (100)
Rectal swabs
Positive 8 (100) 0 8 (100)
0.999
- - -
-Negative 81 (95.2) 4 (4.8) 85 (100) - - -
Sterile bodily fluids
Positive 6 (100) 0 6 (100)
0.999
0 1 (100) 1 (100)
0.999Negative 83 (95.4) 4 (4.4) 87 (100) 4 (18.2) 18 (81.8) 22 (100)
Catheters
Positive 2 (66.6) 1 (33.4) 3 (100)
0.124
- - -
-Negative 87 (96.6) 3 (0.4) 91 (100) - - -
Tracheal aspirates
Positive 1 (100) 0 1 (100)
0.999
- - -
-
Negative 88 (95.6) 4 (4.4) 92 (100) - - -
Sputum
Positive 2 (100) 0 2 (100)
0.999
- - -
-Negative 87 (95.6) 4 (4.4) 93 (100) - - -
Drainage tubes
Positive - - -
-
0 1 (100) 1 (100)
0.999
Negative - - - 4 (18.2) 18 (81.8) 22 (100)
Figure 1. PCR image of 16 strains with vanA genotype: the first 
line (M) is the marker, line 1 is E. faecalis ATCC 51559 (732 bp) 
as a vanA-positive control strain, line 2 is E. faecalis ATCC 51299 
(635 bp) as a vanB-positive control strain, line 3 is the negative 
control, and lines 4–20 are amplification products in specific 732 
bp for the vanA gene in DNAs of strains.
Figure 2. PCR image of VRE esp and cyl VRE: the first line (M) 
is the marker, line 1 is MMH594 as a positive control (esp and 
cyl), line 2 is the negative control, and lines 3, 4, 5, and 6 are am-
plification products in specific 510 bp for the esp gene in DNAs 
of strains.
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were not identified in any VRE strains. The rates of esp, 
hyl, and gelE were 79.8%/100%, 15.7%/0%, and 2.2%/25%, 
respectively, in VRE E. faecium (VREfm)/VRE E. faecalis 
(VREfs) (Table 5). 
At least one virulence factor was found in all VSE 
strains. Of a total of 23 VSE strains, esp was identified in 
16 (69.6%), asa1 was identified in 13 (56.5%), gelE was 
identified in 12 (52.2%), cyl was identified in 8 (34.8%), and 
hyl was identified in 1 (4.3%). Two virulence factors were 
found together in 6 (26.1%) VSE (n = 23) strains, and the 
most common association (n = 4) was esp and gelE. Three or 
more virulence factors were found in a total of 9 (39.13%) 
samples of isolated VSE (n = 23) strains (Table 5).
The esp rate in the VRE clinical samples obtained from 
pediatrics patients was statistically significantly higher (P 
< 0.01). The esp rates in isolates obtained from other clinics 
(neurology, internal medicine, cardiology, geriatrics, 
physical therapy and rehabilitation, gastroenterology, and 
chest disease services) were statistically significant (P < 
0.05) (Table 6).
The rates of esp+hyl and esp+gelE were higher in 
samples obtained from other clinics (neurology, internal 
medicine, cardiology, geriatrics, physical therapy and 
rehabilitation, gastroenterology, and chest disease service), 
intensive care units, and surgery clinics (urology, general 
surgery, orthopedics, and obstetrics). Hyl was the highest 
in pediatrics and intensive care units. The rates of hyl 
and hyl+esp were significantly highest in sputum samples 
(P < 0.05) among all VRE strains obtained from clinical 
samples (Table 7).
The dominant species was E. faecium (89/93) with a 
rate of 95.7% in VRE isolates, whereas it was E. faecalis 
with a rate of 82.6% (19/23) in VSE species. esp was found 
in VSE and VRE strains of both species but was more 
common in VRE isolates. However, this higher rate was 
not statistically significant. VREfm had the highest hyl rate 
Figure 3. PCR image of VRE asa1 and gelE: the first line (M) is 
the marker, line 1 is MMH594 as a positive control (asa1 and 
gelE), line 2 is the negative control, and lines 3, 4, and 6 are ampli-
fication products in specific 213 bp for the gelE gene in DNAs of 
strains. Line 5 is the product without asa1 or gelE genes. 
Figure 5. PCR image of VSE esp and cyl: the first line (M) is the 
marker, line 1 is MMH594 as a positive control (esp and cyl), and 
line 2 is the negative control. Lines 6, 7, 8, 12, 13, 14, 15, 18, 19, 
20, and 21 are amplification products in specific 510 bp for the 
esp gene in DNAs of strains. Lines 7, 8, 16, 18, and 21 are ampli-
fication products in specific 688 bp for the cyl gene in DNAs of 
strains.  
Figure 4. PCR image of the VRE hyl virulence gene: the first line 
(M) is the marker, line 1 is E. faecium C68 (hyl positive control), 
line 2 is the negative control, and all other lines are amplification 
products in specific 276 bp for the hyl gene in DNAs of strains. 
Figure 6. PCR image of VSE asa1 and gelE: the first line (M) is 
the marker, line 1 is MMH594 as a positive control (asa1 and 
gelE), and line 2 is the negative control. Lines 4, 13, 14,15, and 16 
are amplification products in specific 213 bp for the gelE gene in 
DNAs of strains. Lines 3, 4, 7, 11, 13, 14, and 16 are amplification 
products in specific 375 bp for the asa1 gene in DNAs of strains.
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Table 5. Distribution of virulence genes by VRE and VSE.
Resistant Sensitive
E. faecium
(n = 89)
E. faecalis
(n = 4) P
E. faecium
(n = 4)
E. faecalis
(n = 19) P
n (%) n (%) n (%) n (%)
Total esp (78.4%, n = 91) 71 (79.8) 4 (100) 0.999 3 (75.0) 13 (68.4) 0.999
Total hyl (12.9%, n = 15) 14 (15.7) 0 (0) 0.999 0 (0) 1 (5.3) 0.999
Total gelE (12.9%, n = 15) 2 (2.2) 1 (25) 0.125 1 (25) 11 (57.9) 0.317
Total asa1 (11.2%, n = 13) 0 (0) 0 (0) - 2 (50) 11 (57.9) 0.999
Total cyl (6.9%, n = 8) 0 (0) 0 (0) - 2 (50) 6 (31.6) 0.589
esp alone (67.7%, n = 63) 61 (68.5) 0 (0) 0.999 1 (25) 1 (5.2) 0.324
hyl alone (3.2%, n = 3) 3 (3.3) 0 (0) 0.999 0 (0) 0 (0) -
gelE alone (1%, n = 1) 0 (0) 0 (0) - 0 (0) 1 (5.2) 0.999
asa1 alone (2.1%, n = 2) 0 (0) 0 (0) - 0 (0) 2 (10.5) 0.999
cyl alone (n = 0) 0 (0) 0 (0) - 0 (0) 0 (0) -
esp+hyl (n = 12) 11 (12.4) 0 (0) 0.999 0 (0) 1 (5.3) 0.999
esp+gelE (n = 15) 11 (12.4) 0 (0) 0.125 0 (0) 4 (21.1) 0.999
asa1+gelE (n = 1) 0 (0) 0 (0) - 0 (0) 1 (5.3) 0.999
asa1+gelE+cyl (n = 2) 0 (0) 0 (0) - 1 (25) 1 (5.3) 0.324
esp+cyl+asa1 (n = 3) 0 (0) 0 (0) - 1 (25) 2 (10.5) 0.453
asa1+gelE+esp (n = 2) 0 (0) 0 (0) - 0 (0) 2 (10.5) 0.999
asa1+gelE+cyl+esp (n = 2) 0 (0) 0 (0) - 0 (0) 2 (10.5) 0.999
Table 6. According to clinics, virulence genes in isolated distribution of VRE.
esp hyl gelE
Positive Negative Total
P
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Intensive care unit
Positive 14 (70) 6 (30) 20 (100)
0.205
4 (20) 16 (80) 20 (100)
0.491
1 (5) 19 (95) 20 (100)
0.521
Negative 61 (83.6) 12 (16.4) 73 (100) 10 (13.7) 63 (86.3) 73 (100) 2 (2.7) 71 (97.3) 73 (100)
Surgery clinics***
Positive 19 (90.5) 2 (9.5) 21 (100)
0.345
3 (14.3) 18 (85.7) 21 (100)
0.999
2 (9.5) 19 (90.5) 21 (100)
0.127
Negative 56 (77.8) 16 (22.2) 72 (100) 11 (15.5) 61 (84.7) 77 (100) 1 (1.4) 71 (98.6) 72 (100)
Burn units
Positive 6 (85.7) 1 (14.3) 7 (100)
0.999
11 (14.3) 6 (85.7) 17 (100)
0.999
0 7 (100) 7 (100)
0.999
Negative 69 (80.2) 17 (19.8) 86 (100) 13 (15.1) 73 (84.9) 86 (100) 3 (3.5) 83 (96.5) 86 (100)
Nephrology
Positive 9 (81.8) 2 (18.2) 11 (100)
0.999
1 (9.1) 10 (90.9) 11 (100)
0.999
0 11 (100) 11 (100)
0.999
Negative 66 (80.5) 16 (19.5) 82 (100) 13 (15.9) 69 (84.1) 82 (100) 3 (3.7) 79 (96.3) 82 (100)
Hematology
Positive 5 (100) 0 5 (100)
0.579
0 5 (100) 5 (100)
0.999
0 5 (100) 5 (100)
0.999
Negative 70 (79.5) 18 (20.5) 88 (100) 14 (15.9) 74 (81.1) 88 (100) 3 (3.4) 85 (94.4) 88 (100)
Pediatrics
Positive 6 (46.2) 7 (53.8) 13 (100)
0.003**
3 (23.1) 10 (76.9) 13 (100)
0.407
0 13 (100) 13 (100)
0.999
Negative 69 (86.3) 11 (13.8) 80 (100) 11 (13.8) 69 (86.3) 80 (100) 3 (3.8) 77 (96.3) 80 (100)
Other clinics***
Positive 16 (100) 0 16 (100)
0.035*
2 (12.5) 14 (87.5) 16 (100)
0.999
0 16 (100) 16 (100)
0.999
Negative 59 (76.6) 18 (23.4) 77 (100) 12 (15.6) 65 (84.4) 77 (100) 3 (3.9) 74 (96.1) 77 (100)
*P < 0.05;   **P < 0.01.
***Orthopedics, general surgery.
****Neurology, internal medicine, cardiology, geriatrics, physical therapy and rehabilitation, gastroenterology, and chest disease services.
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Table 6. (Continued). 
esp+hyl esp+gelE
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%)
Intensive care unit
Positive 4 (20) 16 (80) 20 (100)
0.242
1 (5) 19 (95) 20 (100)
0.521
Negative 7 (9.6) 66 (90.4) 73 (100) 2 (2.7) 71 (97.3) 73 (100)
Surgery clinics***
Positive 3 (14.3) 18 (85.7) 21 (100)
0.707
2 (9.5) 19 (90.5) 21 (100)
0.127
Negative 8 (11.1) 64 (88.99 72 (100) 1 (1.4) 71 (98.6) 72 (100)
Burn units
Positive 1 (14.3) 6 (85.7) 7 (100)
0.999
0 7 (100) 7 (100)
0.999
Negative 10 (11.6) 76 (88.4) 86 (100) 3 (3.5) 83 (96.5) 86 (100)
Nephrology
Positive 0 11 (100) 11 (100)
0.350
0 11 (100) 11 (100)
0.999
Negative 11 (13.4) 71 (86.6) 82 (100) 3 (3.7) 79 (96.3) 82 (100)
Hematology
Positive 0 5 (100) 5 (100)
0.999
0 5 (100) 5 (100)
0.999
Negative 11 (12.5) 77 (87.5) 88 (100) 3 (3.4) 85 (96.6) 88 (100)
Pediatrics
Positive 1 (7.7) 12 (92.3) 13 (100)
0.999
0 13 (100) 13 (100)
0.999
Negative 10 (12.5) 70 (87.5) 80 (100) 3 (3.8) 77 (96.3) 80 (100)
Other clinics****
Positive 2 (12.5) 14 (87.7) 16 (100)
0.999
0 16 (100) 16 (100)
0.999
Negative 98 (11.7) 68 (88.3) 77 (100) 3 (3.9) 74 (96.1) 77 (100)
Table 7. The distribution of virulence genes in VRE isolated from clinical samples. 
esp hyl gelE
Positive Negative Total
P
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Urine
Positive 24 (72.7) 9 (27.3) 33 (100)
0.177
2 (6.1) 31 (93.9) 33 (100)
0.127
2 (6.1) 31 (93.9) 33 (100)
0.286
Negative 51 (85) 9 (15) 60 (100) 12 (20) 48 (80) 60 (100) 1 (1.7) 59 (98.3) 60 (100)
Blood
Positive 14 (77.8) 4 (22.2) 18 (100)
0.745
5 (27.8) 13 (72.2) 18 (100)
0.136
0 18 (100) 18 (100)
0.999
Negative 61 (81.3) 14 (18.7) 75 (100) 9 (12) 66 (88) 75 (100) 3 (4) 72 (96) 75 (100)
Rectal swabs
Positive 8 (100) 0 8 (100)
0.347
1 (12.5) 7 (87.5) 8 (100)
0.999
0 8 (10.09) 8 (100)
0.999
Negative 67 (78.8) 18 (21.2) 85 (100) 13 (15.3) 72 (84.7) 85 (100) 3 (3.5) 82 (96.5) 85 (100)
Wounds
Positive 18 (90) 2 (10) 20 (100)
0.343
2 (10) 18 (90) 20 (100)
0.726
1 (59) 19 (95) 20 (100)
0.521
Negative 57 (78.1) 16 (21.9) 73 (100) 12 (16.4) 61 (83.6) 73 (100) 2 (2.79) 71 (97.39) 73 (100)
Sterile bodily fluids
Positive 4 (66.7) 2 (33.3) 6 (100)
0.328
0 6 (100) 6 (100)
0.586
0 6 (100) 6 (100)
0.999
Negative 71 (81.6) 16 (18.4) 87 (100) 14 (16.1) 73 (83.9) 87 (100) 3 (3.4) 84 (96.6) 87 (100)
Catheters
Positive 3 (100) 0 3 (100)
0.999
1 (33.3) 2 (66.7) 3 (100)
0.391
0 3 (10.09) 3 (100)
0.999
Negative 72 (80) 18 (20) 90 (100) 13 (14.4) 77 (85.6) 90 (100) 3 (3.3) 87 (96.7) 90 (100)
Sputum 
Positive 2 (100) 0 2 (100)
0.999
2 (100) 0 2 (100)
0.021*
0 2 (100) 2 (100)
0.999
Negative 73 (80.2) 18 (19.8) 91 (100) 12 (13.2) 79 (86.8) 91 (100) 3 (3.3) 88 (96.7) 91 (100)
Drainage tubes
Positive 1 (100) 0 1 (100)
0.999
0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
Negative 74 (80.4) 18 (19.6) 92 (100) 14 (15.2) 78 (84.8) 91 (100) 3 (3.3) 89 (96.7) 92 (100)
*P < 0.05.
**P < 0.01.
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of 15.7%. With a rate of 57.9%, gelE was the highest in the 
VSEfs strains. Asa1 and cyl were not found in VRE strains 
but were detected in VSEfs strains in particular among 
VSE strains. The distributions of virulence genes in VRE 
and VSE according to species are presented in Table 5.
4. Discussion 
Enterococci have become important as isolation rates 
have recently increased in community-acquired and 
nosocomial infections and they have developed resistance 
to many antibiotics, including glycopeptides. Enterococci 
are very common in the world and play important roles 
in nosocomial infections, as the second most common 
nosocomial pathogens after S. aureus in the United States 
(9).
According to data from the National Nosocomial 
Infections Surveillance System, the number of hospitals 
with VRE isolated is increasingly growing in Turkey. This 
rate was 5.4%, 6.1%, 11.2%, and 17.7% respectively for 
2008, 2009, 2010, and 2012 (10,11).
Risk factors for VRE include malignancy, neutropenia, 
intraabdominal surgery, prolonged hospitalization 
duration, transplantation, staying in hematology-oncology 
and intensive care units, antineoplastic therapy, and use of 
vancomycin and 2nd and 3rd generation cephalosporin.  
In a study from Turkey, Aygün et al. (12) reported that 
out of 467 rectal swab samples the VRE rate was 1.9% (n 
= 9). Aral et al. (13) reported that 158 Enterococcus strains 
were isolated from inpatients at various clinics, particularly 
34% from pediatrics, 27% from surgery, and 20% from 
intensive care units in 4 years (13). Of VRE strains in our 
study, 22.6% were isolated from samples of surgery clinics, 
21.5% were isolated from samples of intensive care units, 
and 17.2% were isolated from samples of other clinics.
Aral et al. (13) sorted 158 Enterococcus strains according 
to clinical samples in 4 years and reported that the urine 
samples (58%) took first place, which was followed by 
blood (16%) and wound (17%) samples. A Greek study 
(14) indicated that 37.2% of identified VRE samples were 
isolated from urine samples, followed by 21.5% from blood 
samples and 19.7% from wound samples. Of isolates in our 
study, 37% were from urine, 21.5% wounds, 19.4% blood, 
8.6% rectal swabs, and 6.5% sterile bodily fluids.
In the distribution of Enterococcus spp., the most 
common species are E. faecalis and E. faecium among 
enterococci leading to infection in humans. Despite the 
common species being E. faecalis, the rate of E. faecium 
has significantly increased in resistant enterococci in 
particular over the past years. SENTRY data show that 
VREfm strains increased from 40% to 62% from 1997 to 
2002. In the same period, VREfs decreased from 4% to 
3%. Regardless of the geographic region, currently many 
VRE clinical isolates are E. faecium (15). Wang et al. (16) 
analyzed data from their surveillance study of 8 years and 
Table 7. (Continued). 
esp+hyl esp+gelE
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%)
Urine
Positive 2 (6.1) 31 (93.9) 33 (100)
0.317
2 (6.1) 31 (93.9) 33 (100)
0.286
Negative 9 (15) 51 (85) 60 (100) 1 (1.7) 59 (98.3) 60 (100)
Blood
Positive 3 (16.7) 15 (83.3) 18 (199)
0.440
0 18 (100) 18 (100)
0.999
Negative 8 (10.7) 67 (89.3) 75 (100) 3 (4) 72 (96) 75 (100)
Rectal swabs
Positive 1 (12.5) 7 (87.5) 8 (100)
0.999
0 8 (100) 8 (100)
0.999
Negative 10 (11.8) 75 (88.2) 85 (100) 3 (3.5) 82 (96.5) 85 (100)
Wounds
Positive 2 (10) 18 (90) 20 (100)
0.999
1 (5) 19 (95.5) 20 (100)
0.521
Negative 9 (12.3) 64 (87.7) 73 (100) 2 (2.7) 71 (97.3) 73 (100)
Sterile bodily fluids
Positive 0 6 (100) 6 (100)
0.999
0 6 (100) 6 (100)
0.999
Negative 11 (12.6) 76 (87.4) 87 (100) 3 (3.4) 84 (96.6) 87 (100)
Catheters
Positive 1 (33.3) 2 (66.79) 3 (100)
0.318
0 3 (100) 3 (100)
0.999
Negative 10 (11.1) 80 (88.99) 90 (100) 3 (3.3) 87 (96.79) 90 (100)
Sputum 
Positive 2 (100) 0 2 (100)
0.013**
0 2 (100) 2 (100)
0.999
Negative 9 (9.9) 82 (90.1) 91 (100) 3 (3.3) 88 (96.7) 91 (100)
Drainage tubes
Positive 0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
Negative 11 (12) 81 (88) 92 (100) 3 (3.3) 89 (96.7) 92 (100)
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reported that the rate of E. faecium increased from 12.4% 
(in 2002) to 27.3% (in 2010). In the same surveillance 
study vancomycin resistance rates were also increased.
In the surveillance study (17) of the Hacettepe 
University Faculty of Medicine conducted in 2008, 12 VRE 
were isolated and all of these isolates were E. faecium. Yiş 
et al. (18) evaluated 123 rectal swab samples taken from 
different services and 18 (14.6%) were identified as VRE. 
As reported above, the most common species appear 
to be E. faecium and E. faecalis. Of 93 VRE isolates in our 
study, 95.7% were E. faecium (89/93) and 4.3% were E. 
faecalis (4/93). On the other hand, of VSE strains, 82.6% 
were E. faecalis (19/23) and 17.4% were E. faecium (4/23).
The most significant characteristic of enterococci that 
increases their importance is resistance to glycopeptides. 
The most common MDR1 gene is vanA, which is followed 
by vanB. In vanA type resistance, there is a high level of 
resistance to both vancomycin and teicoplanin. In vanB 
type resistance, there are various degrees of resistance 
to vancomycin, and sensitivity to teicoplanin. Both of 
the resistance types can be induced. The vanA resistance 
phenotype is more common in the United States and 
European countries as compared to others. A study by 
Protonotariou et al. (14) conducted in 2010 with 2123 
Enterococcus isolates investigated MDR1 gene areas 
and identified 79.1% as vanA and 20.9% as vanB MDR1 
genes. The results of a surveillance study (19) performed 
in Canada between 1999 and 2009 revealed that 81 of 128 
VRE samples causing bacteremia were E. faecium, and 
90.1% of them had vanA while 9.9% had vanB MDR1 gene 
areas (19). Çakırlar et al. (20) reported that all VRE strains 
included in their study harbored the vanA gene.
In the present study, 19.8% of total strains (23/116) 
were sensitive to vancomycin and teicoplanin, while 93 
(80.17%) were resistant to both antibiotics. The vanA 
resistance type was present in all of the VRE strains. It was 
expected to identify the vanA resistance type because a 
large part of enterococci in this study were E. faecium.
In addition to MDR1 gene areas, the presence of 
virulence genes in enterococci is important in colonization 
of bacteria and occurrence of infections. We investigated 
the presence of virulence gene areas in a total of 116 
Enterococcus strains, 93 being VRE and 23 being VSE. 
The esp enterococcal surface protein, expressed on the 
surface of bacteria, can be transferred to other enterococci 
through conjugation. A high amount of esp is found in 
isolates causing bacteremia and endocarditis despite its 
low amount in enterococci isolated from stool samples (1). 
esp is thought to protect bacteria from the immune system 
of the host and is known to increase colonization in the 
urinary system, contributing to persistence (5). Expression 
of esp is correlated with formation of biofilm. Although esp 
is common in E. faecalis isolates, it is more common in 
hospital-acquired E. faecium isolates in particular (4). The 
rate of esp expression in enterococcal isolates is 49.5%–
77% (21–23) in Asian countries, 33%–65% (8,24,25) in 
European countries, and 33%–76% in continental America 
(26–28). A study (29) conducted in Turkey reported that 
this rate was 25.6%. The esp virulence gene had the highest 
rate at 78.4% in our study. In Asian studies, the esp gene 
rates of species were 71%–87.5% for E. faecium, whereas 
they varied between 0% and 100% for E. faecalis (21,30,31). 
We found esp gene rates of species to be 79.8% in VRE 
E. faecium and 100% in VRE E. faecalis, 75% in VSE E. 
faecium, and 68.49% in VSE E. faecalis, and no statistical 
correlation was present between the virulence gene and 
species (Table 5). 
In a previous study esp gene rates for VRE and VSE 
were 85.7% and 44.2%, respectively (32). In another study, 
out of 135 strains, 73 were VRE and 62 were VSE, and esp 
gene rates were 79.5% and 54.8%, respectively (33). In our 
study the esp gene rates for VRE and VSE were 79.8% and 
75%, respectively (Table 5).
For VRE, the clinic where esp was most often isolated 
was hematology, and other clinics were 100%, while 
surgery clinics were 90.5%, burn clinics were 85.7%, 
nephrology was 81.8%, intensive care units were 7%, and 
pediatrics was 46.2%. The rate of the esp gene in strains 
isolated from pediatrics and other clinics was statistically 
significantly higher (P < 0.005) (Table 6). Most of our 
isolates were enterococci grown in urine samples, which 
was followed by wound and blood samples: 72.7% of urine 
samples had the esp gene (Table 7).
It was an interesting finding that the presence of the 
esp virulence gene area was higher than 40% in enterococci 
isolated from clinics other than intensive care units (Table 6).
The esp gene was detected from internal disease 
polyclinic patients at a rate of 100%, surgery polyclinic 
patients at a rate of 50%, and internal medicine intensive 
care units at 33.3%. Additionally, 100% of enterococci 
isolated from blood samples, 75% from sterile bodily fluids 
and wound samples, and 63.6% from urine samples had 
the esp virulence gene area (Tables 8 and 9). The existence 
of studies reporting that esp is thought to protect bacteria 
from the immune system of the host and is known to 
increase colonization in infections explains why the 
esp gene was mostly found in blood, sterile body fluids, 
wound, and urine samples. 
Wıth regard to the presence of the hyl virulence gene 
area, the rate of hyl was 4%–7% in European countries 
(8,24,34,35), 17.2%–100% in continental America 
(27,36,37), and 53% in Saudi Arabia (38) in VSE strains. 
We found that 12.9% of all isolates had the hyl gene in this 
study. A Chinese study (30) conducted in 2012 with VRE 
reported that the rate of hyl was 31.3% in E. faecium and 
no hyl was found in E. faecalis. 
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In this study, the rate of hyl was 15.5% and 4.3% 
respectively in E. faecium and E. faecalis in all isolates, 
whereas this rate was 15.7% in VREfm isolates but 0% 
in VREfs isolates. The hyl gene is a virulence factor that 
facilitates the spread of bacteria and toxins over tissues. 
The results of our study are consistent with the results of 
European and American studies for the hyl gene area. We 
found hyl to be the most commonly found virulence factor 
after esp in VRE strains. This factor was only found in one 
sample of VSEfs strains. 
hyl was mostly isolated from pediatrics (23.1%), 
intensive care units (20%), and other clinic patients (17.6%) 
in VRE isolates and was mostly found in enterococci 
isolated from sputum (100%), catheter (33.3%), and blood 
(27.8%) samples. The association of hyl and hyl plus esp 
was statistically significant in enterococci isolated from 
sputum samples (P < 0.021, P < 0.013). 
The rate of gelE was 12.9% in all isolates. The incidence 
rates of gelE were 27%–65.9% (21,22,39) in Asia, 60% in 
continental America (28), and 74.3% in Europe (40). Our 
rate was very low as compared to the rates of other studies. 
This can be considered a state specific to Turkey. 
The gelE rates were 2% and 25% respectively in VREfm 
and VREfs, whereas it was 25% and 57.9% in VSEfm and 
VSEfs. 
The rate of the asa1 gene was 11.1% in the present 
study. The percentage of the asa1 gene was 50% in VSEfm 
and 57.9% in VSEfs. The rate of the asa1 gene was 23%–
53.6% (21,22,39) in Asian studies and 63.5% (40) in a 
European study. These rates varied between 26.7% and 
40% in Turkish studies (29,41). This gene was not found 
in our VRE strains. The asa1 virulence gene is a virulence 
factor that allows bacteria to attach to eukaryotic surfaces, 
facilitating development of systemic infections. This result 
of our study is highly interesting. Although we did not 
detect this gene area in VRE strains, it is important that it 
was found in VSE strains. 
The rate of the cyl gene was 6.8% in all isolates. Many 
studies did not find cyl in VRE isolates (8,36,42,43). We 
did not find cyl in VRE but did find it in VSE isolates with 
a rate of 6.9%. It is important to detect the cyl protein with 
cytolytic activity in VSE for nosocomial bacteremia caused 
by VSE strains. 
In this study, all 15 strains without virulence factors 
were VRE. Although we detected one to four virulence 
genes in all of our VSE, we found a maximum of two 
virulence genes in VRE strains. 
The association of esp and hyl was mostly present in 
VRE strains at 12.4%, whereas this rate was 5.3% in VSE 
strains. The rate of isolates with esp plus gelE was 6% in this 
study. These rates were 21.1%, 25%, and 2.2% respectively 
in VSEfs, VREfs, and VREfm.
Isolates with three or more virulence genes were found 
in urine and wound samples isolated from surgery and 
internal medicine polyclinics. 
VRE are primary agents to consider in clinical 
approaches, and there is a common opinion that measures 
should be taken for nosocomial infections. However, 
virulence factors of bacteria are important in the spreading 
of infections caused by enterococci over tissues and organs. 
We consider that it is a significant result that VSE had more 
virulence genes than VRE. Based on these findings, it is 
Table 8. (Continued). 
esp hyl gelE
Positive Negative Total
P
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Surgery polyclinics*
Positive 2 (20) 8 (80) 10 (100)
0.405
0 10 (100) 10 (100)
0.999
1 (10) 9 (90) 10 (100)
0.604
Negative 5 (38.5) 8 (61.5) 13 (100) 1 (7.7) 12 (92.3) 13 (100) 3 (23.1) 10 (76.9) 13 (100)
Internal polyclinics#
Positive 1 (20) 4 (80) 5 (100)
0.999
1 (20) 4 (80) 5 (100)
0.217
1 (20) 4 (80) 5 (100)
0.999
Negative 6 (33.3) 1 (66.7) 18 (100) 0 18 (100) 18 (100) 3 (16.7) 15 (83.3) 18 (100)
Internal intensive 
care units
Positive 2 (66.7) 1 (33.3) 3 (100)
0.209
0 3 (100) 3 (100)
0.999
0 3 (100) 3 (100)
0.999
Negative 5 (25) 15 (75) 20 (100) 1 (5) 19 (95) 20 (100) 4 (20) 16 (80) 20 (100)
Surgery clinics**
Positive 1 (50) 1 (50) 2 (100)
0.526
0 2 (100) 2 (100)
0.999
1 (50) 1 (50) 2 (100)
0.324
Negative 6 (28.6) 15 (71.4) 21 (100) 1 (4.8) 20 (95.2) 21 (100) 3 (14.3) 18 (85.79) 21 (100)
Pediatrics
Positive 1 (50) 1 (50) 2 (100)
0.526
0 2 (100) 2 (100)
0.999
1 (50) 1 (50) 2 (100)
0.324
Negative 6 (28.6) 15 (71.4) 21 (100) 1 (4.8) 20 (95.2) 2 (100) 3 (14.3) 18 (85.79 21 (100)
Hematology
Positive 0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
Negative 78 (31.8) 15 (68.2) 22 (100) 1 (4.5) 21 (95.5) 22 (100) 4 (18.2) 18 (81.8) 22 (100)
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important and necessary to investigate MDR1 gene areas 
in the pathogenicity of enterococci as well as to investigate 
virulence genes in both VRE and VRE strains. 
This study includes in vitro results of the association of 
virulence characteristics in VRE and VSE strains. VRE are 
important causes of difficult-to-treat infections, especially 
in hospitalized patients. According to our results, VSE 
are also important microorganisms due to their virulence 
factors. Vancomycin resistance virulence factors should 
also be taken into consideration. In conclusion, we 
think that not only VRE but also VSE may cause serious 
infections. In our opinion, new studies extended with 
clinical findings, hospitalization duration, severity of 
infection, and treatment protocols would help further 
clarify the subject.
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Table 9. (Continued). 
esp hyl gelE
Positive Negative Total
P
Positive Negative Total
P
Positive Negative Total
P
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Urine
Positive 3 (27.3) 8 (72.7) 11 (100)
0.999
1 (9.1) 10 (90.9) 11 (100)
0.478
1 (9.1) 10 (90.9) 11 (100)
0.590
Negative 4 (33.3) 8 (66.79) 12 (100) 0 12 (100) 12 (100) 3 (25) 9 (75) 12 (100)
Blood
Positive 1 (50) 1 (50) 2 (100)
0.526
0 2 (100) 2 (100)
0.999
0 2 (100) 2 (100)
0.999
Negative 6 (28.6) 15 (71.4) 21 (100) 1 (4.8) 20 (95.2) 21 (100) 4 (19) 17 (81) 21 (100)
Wounds
Positive 2 (25) 6 (75) 8 (100)
0.999
0 8 (100) 8 (100)
0.999
3 (37.5) 5 (62.5) 8 (100)
0.103
Negative 5 (33.3) 10 (66.7) 15 (100) 1 (6.7) 14 (93.3) 15 (100) 1 (6.7) 14 (93.3) 15 (100)
Sterile bodily fluids
Positive 1 (100) 0 1 (100)
0.304
0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
Negative 6 (27.3) 16 (72.7) 22 (100) 1 (4.5) 21 (95.5) 22 (100) 4 (18.2) 18 (81.8) 22 (100)
Drainage tubes
Positive 0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
0 1 (100) 1 (100)
0.999
Negative 7 (31.8) 15 (68.2) 22 (100) 1 (4.5) 21 (95.5) 22 (100) 4 (18.2) 18 (81.8) 22 (100)
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